Needham & Company LLC Reiterates “Hold” Rating for Amicus Therapeutics (NASDAQ:FOLD)

Amicus Therapeutics (NASDAQ:FOLD)‘s stock had its “hold” rating reiterated by research analysts at Needham & Company LLC in a report released on Thursday,Benzinga reports.

Several other analysts have also commented on the stock. StockNews.com lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday. Morgan Stanley reissued an “equal weight” rating and issued a $12.00 target price (down previously from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. Cantor Fitzgerald reissued an “overweight” rating and issued a $21.00 target price on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. Guggenheim boosted their target price on Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Finally, JPMorgan Chase & Co. boosted their target price on Amicus Therapeutics from $16.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, November 12th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $16.75.

Amicus Therapeutics Stock Up 1.3 %

FOLD stock opened at $9.19 on Thursday. The firm has a market cap of $2.75 billion, a PE ratio of -51.06, a PEG ratio of 1.60 and a beta of 0.61. The company has a debt-to-equity ratio of 2.18, a quick ratio of 2.42 and a current ratio of 3.15. The firm’s 50 day moving average price is $9.56 and its 200-day moving average price is $10.41. Amicus Therapeutics has a one year low of $8.78 and a one year high of $14.02.

Insiders Place Their Bets

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $10.02, for a total value of $75,150.00. Following the completion of the transaction, the chief executive officer now owns 886,654 shares in the company, valued at $8,884,273.08. The trade was a 0.84 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 2.20% of the company’s stock.

Hedge Funds Weigh In On Amicus Therapeutics

Institutional investors have recently modified their holdings of the business. Creative Planning grew its stake in shares of Amicus Therapeutics by 79.6% during the third quarter. Creative Planning now owns 52,855 shares of the biopharmaceutical company’s stock worth $564,000 after purchasing an additional 23,433 shares in the last quarter. Blue Trust Inc. grew its stake in shares of Amicus Therapeutics by 1,705.4% during the third quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 2,831 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in shares of Amicus Therapeutics by 141.1% during the third quarter. Assenagon Asset Management S.A. now owns 2,037,896 shares of the biopharmaceutical company’s stock worth $21,765,000 after purchasing an additional 1,192,489 shares in the last quarter. Legacy Capital Group California Inc. acquired a new position in shares of Amicus Therapeutics during the third quarter worth $206,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Amicus Therapeutics by 21.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,727 shares of the biopharmaceutical company’s stock worth $115,000 after purchasing an additional 1,884 shares in the last quarter.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.